Tests repeat laser treatment for early glaucoma and high eye pressure
Tests a repeated laser treatment in adults with early glaucoma or high eye pressure.
Plain-language title generated from the registry record
Registry title: Glaucoma Laser Assessment of Stability and Sustainability
Key facts
- Where
- Coon Rapids, United StatesSee the site
Where in United States
- Twin Cities Eye ConsultantsCoon Rapids, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Twin Cities Eye Consultants
- Trial code
- NCT06963684
- Record updated
- 14 May 2025
- Original description
The GLASS Study is designed to help researchers learn whether repeating a non-invasive laser treatment called DSLT (Direct Selective Laser Trabeculoplasty) can better control eye pressure in patients with early-stage glaucoma or ocular hypertension. All participants will receive the laser treatment in both eyes. After three months, one eye will be randomly selected to receive a second treatment, while the other eye will serve as a comparison. The goal is to see whether two treatments work better than one at keeping eye pressure low without using daily eye drops. This study will help doctors decide the best way to use this laser treatment to manage glaucoma and delay the need for medication. Participants will be followed for one year to monitor safety, eye pressure, and the need for any additional treatments.Read full original descriptionShow less
Glaucoma Laser Assessment of Stability and Sustainability: Evaluating Long-Term Stability and Retreatment Efficacy of DSLT in Patients With Ocular Hypertension, Glaucoma Suspects, and Mild/Moderate POAG.
The GLASS Study is designed to help researchers learn whether repeating a non-invasive laser treatment called DSLT (Direct Selective Laser Trabeculoplasty) can better control eye pressure in patients with early-stage glaucoma or ocular hypertension. All participants will receive the laser treatment in both eyes. After three months, one eye will be randomly selected to receive a second treatment, while the other eye will serve as a comparison. The goal is to see whether two treatments work better than one at keeping eye pressure low without using daily eye drops. This study will help doctors decide the best way to use this laser treatment to manage glaucoma and delay the need for medication. Participants will be followed for one year to monitor safety, eye pressure, and the need for any additional treatments.
Inclusion: Male and female patients aged 40 years or older; A bilateral diagnosis of ocular hypertension, glaucoma suspect, or mild primary open angle glaucoma as defined by AAO PPP; Treatment naïve with an unmedicated IOP between 21-35 mmHg, inclusive, and within +/- 3mmHg of each eye to be eligible; BCVA of 20/50 or better; The subject is able to read and understand the requirements of the study and provide written informed consent; The subject is willing to follow study instructions, agrees to comply with all study procedures and attend all scheduled follow-up exams for 12 months after the initial treatment.
Exclusion: Use of oral or ocular hypotensive medication for glaucoma; Prior history of ocular surgery except for cataract surgery (must be ≥ 2 years prior); Clinically significant ocular inflammation or infection within 6 months prior to screening; Previous corneal transplant or clinically significant corneal dystrophy, e.g., Fuch's dystrophy (≥12 confluent guttae); Current participation in another investigational drug or device clinical trial (which includes the fellow eye) within the past 30 calendar days; Pregnant or nursing women; or women of childbearing age not using medically acceptable contraceptives; Accepted prior ocular procedures:; Uncontrolled systemic disease that in the opinion of the Investigator would put the subject's health at risk and/or prevent the subject from completing all study visits; Clinically significant ocular pathology, other than cataract and glaucoma, including but not limited to neovascular age-related macular degeneration, advanced dry macular degeneration, and proliferative diabetic retinopathy, etc; Cataract surgery (if ≥ 2 years or screening); Unable to view scleral spur inferiorly with gonioscopy; Congenital or developmental glaucoma, angle closure glaucoma, secondary glaucoma (e.g. exfoliative, pigmentary, etc.) pigmentary, neovascular glaucoma, closed angle glaucoma, or uveitic glaucoma; Unclear ocular media prevent visualization of the fundus or anterior chamber angle; YAG capsulotomy (if ≥ 60 days of screening).